Table 1. Summary of ongoing studies with MET inhibitors in the drug resistance setting.

Study ID	Experimental drug	Drug class	Treatment combination	Phase	Patient population	Biomarker selection targets
NCT02468661	Capmatinib	MET TKI	Alone or with Erlotinib	II	Advanced EGFR-mutated NSCLC	EGFRm+, MET GCN >6
NCT02205398	Capmatinib	MET TKI	Cetuximab	I/II	Advanced Squamous Cell Carcinoma of Head and Neck, Metastatic Colorectal Cancer	K-Ras/N-Ras- CRC, cMet-positive (combination of IHC and FISH)
NCT01982955	Tepotinib (MSC2156119J)	MET TKI	Gefitinib	I/II	Advanced EGFR mutation+ NSCLC, failed prior EGFR TKI	EGFRm+, (ph II limited to MET IHC+, T790M-)
NCT02143466	Volitinib (AZD6094)	MET TKI	AZD9291	I/II	Advanced EGFR-mutation+ NSCLC, failed prior EGFR TKI	EGFRm+ (MET+ and T790M- for ph II)
NCT02260531	Cabozantinib	Multi-targeted TKI	Trastuzumab (if ErbB2+)	II	Breast cancer, metastatic brain disease	No biomarker selection
NCT01644773	Crizotinib	Multi-targeted TKI	Dasatinib	I	Diffuse intrinsic pontine glioma, high-grade glioma	No biomarker selection
NCT01900652	LY2875358	Anti-MET monoclonal antibody	Alone or with erlotinib	II	Advanced EGFR-mutation+ NSCLC, failed prior EGFR TKI	MET IHC+
NCT02318368	Ficlatuzumab	Anti-HGF monoclonal antibody	Erlotinib	II	Advanced EGFR-mutation+ NSCLC, EGFR TKI-naive	EGFRm+ and BDX004 positive